HIV-specific antibodies capable of ADCC are common in breastmilk and are associated with reduced risk of transmission in women with high viral loads

PLoS Pathogens

Volumn 8, Issue 6, 2012, Pages

  Mabuka, Jennifer ^a,b   Nduati, Ruth ^c   Odem Davis, Katherine ^a   Peterson, Dylan ^a   Overbaugh, Julie ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF NAIROBI   (Kenya)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY;

ANTIBODY DETECTION; ARTICLE; BREAST MILK; HUMAN IMMUNODEFICIENCY VIRUS 1; INFECTION RISK; VIRUS LOAD; VIRUS TRANSMISSION; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; CHEMISTRY; DISEASE TRANSMISSION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTIBODIES, NEUTRALIZING; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MILK, HUMAN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VIRAL LOAD;

EID: 84864055665     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1002739     Document Type: Article

References (90)

1. Hosea Blewett HJ, Cicalo MC, Holland CD, Field CJ, (2008) The immunological components of human milk. Adv Food Nutr Res 54: 45-80.
2. Garofalo R, (2010) Cytokines in human milk. J Pediatr 156: S36-40.
3. Oddy WH, (2002) The impact of breastmilk on infant and child health. Breastfeed Rev 10: 5-18.
4. Lawrence RM, Pane CA, (2007) Human breast milk: current concepts of immunology and infectious diseases. Curr Probl Pediatr Adolesc Health Care 37: 7-36.
5. Dunn DT, Newell ML, Ades AE, Peckham CS, (1992) Risk of human immunodeficiency virus type 1 transmission through breastfeeding. Lancet 340: 585-588.
6. Nduati R, John G, Mbori-Ngacha D, Richardson B, Overbaugh J, et al. (2000) Effect of breastfeeding and formula feeding on transmission of HIV-1: a randomized clinical trial. JAMA 283: 1167-1174.
7. Coutsoudis A, Dabis F, Fawzi W, Gaillard P, Haverkamp G, et al. (2004) Late postnatal transmission of HIV-1 in breast-fed children: an individual patient data meta-analysis. J Infect Dis 189: 2154-2166.
8. Homsy J, Moore D, Barasa A, Were W, Likicho C, et al. (2010) Breastfeeding, mother-to-child HIV transmission, and mortality among infants born to HIV-Infected women on highly active antiretroviral therapy in rural Uganda. J Acquir Immune Defic Syndr 53: 28-35.
9. Obimbo EM, Mbori-Ngacha DA, Ochieng JO, Richardson BA, Otieno PA, et al. (2004) Predictors of early mortality in a cohort of human immunodeficiency virus type 1-infected african children. Pediatr Infect Dis J 23: 536-543.
10. Kafulafula G, Hoover DR, Taha TE, Thigpen M, Li Q, et al. (2010) Frequency of gastroenteritis and gastroenteritis-associated mortality with early weaning in HIV-1-uninfected children born to HIV-infected women in Malawi. J Acquir Immune Defic Syndr 53: 6-13.
11. Thior I, Lockman S, Smeaton LM, Shapiro RL, Wester C, et al. (2006) Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana: a randomized trial: the Mashi Study. JAMA 296: 794-805.
12. Kagaayi J, Gray RH, Brahmbhatt H, Kigozi G, Nalugoda F, et al. (2008) Survival of infants born to HIV-positive mothers, by feeding modality, in Rakai, Uganda. PLoS ONE 3: e3877.
13. Creek TL, Kim A, Lu L, Bowen A, Masunge J, et al. (2010) Hospitalization and mortality among primarily nonbreastfed children during a large outbreak of diarrhea and malnutrition in Botswana, 2006. J Acquir Immune Defic Syndr 53: 14-19.
14. Kuhn L, Aldrovandi GM, Sinkala M, Kankasa C, Semrau K, et al. (2008) Effects of early, abrupt weaning on HIV-free survival of children in Zambia. N Engl J Med 359: 130-141.
15. Taha T, Nour S, Li Q, Kumwenda N, Kafulafula G, et al. (2010) The effect of human immunodeficiency virus and breastfeeding on the nutritional status of African children. Pediatr Infect Dis J 29: 514-518.
16. Kuhn L, Sinkala M, Thea DM, Kankasa C, Aldrovandi GM, (2009) HIV prevention is not enough: child survival in the context of prevention of mother to child HIV transmission. J Int AIDS Soc 12: 36.
17. Doherty T, Sanders D, Goga A, Jackson D, (2011) Implications of the new WHO guidelines on HIV and infant feeding for child survival in South Africa. Bull World Health Organ 89: 62-67.
18. Horvath T, Madi BC, Iuppa IM, Kennedy GE, Rutherford G, et al. (2009) Interventions for preventing late postnatal mother-to-child transmission of HIV. Cochrane Database Syst Rev pp. CD006734.
19. John GC, Richardson BA, Nduati RW, Mbori-Ngacha D, Kreiss JK, (2001) Timing of breast milk HIV-1 transmission: a meta-analysis. East Afr Med J 78: 75-79.
20. Humphrey JH, Marinda E, Mutasa K, Moulton LH, Iliff PJ, et al. (2010) Mother to child transmission of HIV among Zimbabwean women who seroconverted postnatally: prospective cohort study. BMJ 341: c6580.
21. Kuhn L, Trabattoni D, Kankasa C, Semrau K, Kasonde P, et al. (2005) Alpha-defensins in the prevention of HIV transmission among breastfed infants. J Acquir Immune Defic Syndr 39: 138-142.
22. Bosire R, John-Stewart GC, Mabuka JM, Wariua G, Gichuhi C, et al. (2007) Breast milk alpha-defensins are associated with HIV type 1 RNA and CC chemokines in breast milk but not vertical HIV type 1 transmission. AIDS Res Hum Retroviruses 23: 198-203.
23. Naarding MA, Dirac AM, Ludwig IS, Speijer D, Lindquist S, et al. (2006) Bile salt-stimulated lipase from human milk binds DC-SIGN and inhibits human immunodeficiency virus type 1 transfer to CD4+ T cells. Antimicrob Agents Chemother 50: 3367-3374.
24. Lohman BL, Slyker J, Mbori-Ngacha D, Bosire R, Farquhar C, et al. (2003) Prevalence and magnitude of human immunodeficiency virus (HIV) type 1-specific lymphocyte responses in breast milk from HIV-1-seropositive women. J Infect Dis 188: 1666-1674.
25. Tuaillon E, Valea D, Becquart P, Al Tabaa Y, Meda N, et al. (2009) Human milk-derived B cells: a highly activated switched memory cell population primed to secrete antibodies. J Immunol 182: 7155-7162.
26. Sabbaj S, Edwards BH, Ghosh MK, Semrau K, Cheelo S, et al. (2002) Human immunodeficiency virus-specific CD8(+) T cells in human breast milk. J Virol 76: 7365-7373.
27. Kliks SC, Wara DW, Landers DV, Levy JA, (1994) Features of HIV-1 that could influence maternal-child transmission. JAMA 272: 467-474.
28. Wolinsky SM, Wike CM, Korber BT, Hutto C, Parks WP, et al. (1992) Selective transmission of human immunodeficiency virus type-1 variants from mothers to infants. Science 255: 1134-1137.
29. Dickover RE, Garratty EM, Plaeger S, Bryson YJ, (2001) Perinatal transmission of major, minor, and multiple maternal human immunodeficiency virus type 1 variants in utero and intrapartum. J Virol 75: 2194-2203.
30. Ahmad N, Baroudy BM, Baker RC, Chappey C, (1995) Genetic analysis of human immunodeficiency virus type 1 envelope V3 region isolates from mothers and infants after perinatal transmission. J Virol 69: 1001-1012.
31. Barbas CF 3rd, Bjorling E, Chiodi F, Dunlop N, Cababa D, et al. (1992) Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro. Proc Natl Acad Sci U S A 89: 9339-9343.
32. Dickover R, Garratty E, Yusim K, Miller C, Korber B, et al. (2006) Role of maternal autologous neutralizing antibody in selective perinatal transmission of human immunodeficiency virus type 1 escape variants. J Virol 80: 6525-6533.
33. Lamers SL, Sleasman JW, She JX, Barrie KA, Pomeroy SM, et al. (1994) Persistence of multiple maternal genotypes of human immunodeficiency virus type I in infants infected by vertical transmission. J Clin Invest 93: 380-390.
34. Mellquist JL, Becker-Pergola G, Gu J, Guay L, Himes L, et al. (1999) Dual transmission of subtype A and D HIV type 1 viruses from a Ugandan woman to her infant. AIDS Res Hum Retroviruses 15: 217-221.
35. Nowak P, Karlsson AC, Naver L, Bohlin AB, Piasek A, et al. (2002) The selection and evolution of viral quasispecies in HIV-1 infected children. HIV Med 3: 1-11.
36. Scarlatti G, Albert J, Rossi P, Hodara V, Biraghi P, et al. (1993) Mother-to-child transmission of human immunodeficiency virus type 1: correlation with neutralizing antibodies against primary isolates. J Infect Dis 168: 207-210.
37. Verhofstede C, Demecheleer E, De Cabooter N, Gaillard P, Mwanyumba F, et al. (2003) Diversity of the human immunodeficiency virus type 1 (HIV-1) env sequence after vertical transmission in mother-child pairs infected with HIV-1 subtype A. J Virol 77: 3050-3057.
38. Zhang H, Rola M, West JT, Tully DC, Kubis P, et al. (2010) Functional properties of the HIV-1 subtype C envelope glycoprotein associated with mother-to-child transmission. Virology 400: 164-174.
39. Wu X, Parast AB, Richardson BA, Nduati R, John-Stewart G, et al. (2006) Neutralization escape variants of human immunodeficiency virus type 1 are transmitted from mother to infant. J Virol 80: 835-844.
40. Scarlatti G, Leitner T, Halapi E, Wahlberg J, Marchisio P, et al. (1993) Comparison of variable region 3 sequences of human immunodeficiency virus type 1 from infected children with the RNA and DNA sequences of the virus populations of their mothers. Proc Natl Acad Sci USA 90: 1721-1725.
41. Barin F, Jourdain G, Brunet S, Ngo-Giang-Huong N, Weerawatgoompa S, et al. (2006) Revisiting the role of neutralizing antibodies in mother-to-child transmission of HIV-1. J Infect Dis 193: 1504-1511.
42. Samleerat T, Thenin S, Jourdain G, Ngo-Giang-Huong N, Moreau A, et al. (2009) Maternal neutralizing antibodies against a CRF01_AE primary isolate are associated with a low rate of intrapartum HIV-1 transmission. Virology 387: 388-394.
43. Husson RN, Lan Y, Kojima E, Venzon D, Mitsuya H, et al. (1995) Vertical transmission of human immunodeficiency virus type 1: autologous neutralizing antibody, virus load, and virus phenotype. J Pediatr 126: 865-871.
44. Hengel RL, Kennedy MS, Steketee RW, Thea DM, Abrams EJ, et al. (1998) Neutralizing antibody and perinatal transmission of human immunodeficiency virus type 1. New York City Perinatal HIV Transmission Collaborative Study Group. AIDS Res Hum Retroviruses 14: 475-481.
45. Russell ES, Kwiek JJ, Keys J, Barton K, Mwapasa V, et al. (2011) The genetic bottleneck in vertical transmission of subtype C HIV-1 is not driven by selection of especially neutralization-resistant virus from the maternal viral population. J Virol 85: 8253-8262.
46. Lynch JB, Nduati R, Blish CA, Richardson BA, Mabuka JM, et al. (2011) The breadth and potency of passively acquired human immunodeficiency virus type 1-specific neutralizing antibodies do not correlate with the risk of infant infection. J Virol 85: 5252-5261.
47. Duprat C, Mohammed Z, Datta P, Stackiw W, Ndinya-Achola JO, et al. (1994) Human immunodeficiency virus type 1 IgA antibody in breast milk and serum. Pediatr Infect Dis J 13: 603-608.
48. Becquart P, Chomont N, Roques P, Ayouba A, Kazatchkine MD, et al. (2002) Compartmentalization of HIV-1 between breast milk and blood of HIV-infected mothers. Virology 300: 109-117.
49. Kuhn L, Trabattoni D, Kankasa C, Sinkala M, Lissoni F, et al. (2006) Hiv-specific secretory IgA in breast milk of HIV-positive mothers is not associated with protection against HIV transmission among breast-fed infants. J Pediatr 149: 611-616.
50. Sagar M, (2010) HIV-1 transmission biology: selection and characteristics of infecting viruses. J Infect Dis 202 (Suppl 2): S289-296.
51. Rousseau CM, Nduati RW, Richardson BA, Steele MS, John-Stewart GC, et al. (2003) Longitudinal analysis of human immunodeficiency virus type 1 RNA in breast milk and of its relationship to infant infection and maternal disease. J Infect Dis 187: 741-747.
52. Rousseau CM, Nduati RW, Richardson BA, John-Stewart GC, Mbori-Ngacha DA, et al. (2004) Association of levels of HIV-1-infected breast milk cells and risk of mother-to-child transmission. J Infect Dis 190: 1880-1888.
53. John-Stewart G, Mbori-Ngacha D, Ekpini R, Janoff EN, Nkengasong J, et al. (2004) Breast-feeding and Transmission of HIV-1. J Acquir Immune Defic Syndr 35: 196-202.
54. Semrau K, Ghosh M, Kankasa C, Sinkala M, Kasonde P, et al. (2008) Temporal and lateral dynamics of HIV shedding and elevated sodium in breast milk among HIV-positive mothers during the first 4 months of breast-feeding. J Acquir Immune Defic Syndr 47: 320-328.
55. Fouda GG, Yates NL, Pollara J, Shen X, Overman GR, et al. (2011) HIV-specific functional antibody responses in breast milk mirror those in plasma and are primarily mediated by IgG antibodies. J Virol.
56. Panteleeff DD, John G, Nduati R, Mbori-Ngacha D, Richardson B, et al. (1999) Rapid method for screening dried blood samples on filter paper for human immunodeficiency virus type 1 DNA. J Clin Microbiol 37: 350-353.
57. Neilson J, John G, Carr JK, Lewis P, Kreiss JK, et al. (1999) Subtypes of HIV-1 and disease stage among women in Nairobi, Kenya. J Virol 73: 4393-4403.
58. Hirbod T, Kaul R, Reichard C, Kimani J, Ngugi E, et al. (2008) HIV-neutralizing immunoglobulin A and HIV-specific proliferation are independently associated with reduced HIV acquisition in Kenyan sex workers. Aids 22: 727-735.
59. Long EM, Rainwater SM, Lavreys L, Mandaliya K, Overbaugh J, (2002) HIV type 1 variants transmitted to women in Kenya require the CCR5 coreceptor for entry, regardless of the genetic complexity of the infecting virus. AIDS Res Hum Retroviruses 18: 567-576.
60. Poss M, Overbaugh J, (1999) Variants from the diverse virus population identified at seroconversion of a clade A human immunodeficiency virus type 1-infected woman have distinct biological properties. J Virol 73: 5255-2564.
61. Blish CA, Nedellec R, Mandaliya K, Mosier DE, Overbaugh J, (2007) HIV-1 subtype A envelope variants from early in infection have variable sensitivity to neutralization and to inhibitors of viral entry. AIDS 21: 693-702.
62. Pineda MJ, Orton BR, Overbaugh J, (2007) A TRIM5alpha-independent post-entry restriction to HIV-1 infection of macaque cells that is dependent on the path of entry. Virology 363: 310-318.
63. Ott D, Friedrich R, Rein A, (1990) Sequence analysis of amphotropic and 10A1 murine leukemia viruses: close relationship to mink cell focus-inducing viruses. J Virol 64: 757-766.
64. Fenyo EM, Heath A, Dispinseri S, Holmes H, Lusso P, et al. (2009) International network for comparison of HIV neutralization assays: the NeutNet report. PLoS One 4: e4505.
65. Sather DN, Armann J, Ching LK, Mavrantoni A, Sellhorn G, et al. (2009) Factors Associated with the Development of Cross-Reactive Neutralizing Antibodies during Human Immunodeficiency Virus Type 1 Infection. J Virol 83: 757-769.
66. Blish CA, Sather DN, Sellhorn G, Stamatatos L, Sun Y, et al. (2010) Comparative immunogenicity of subtype a Human Immunodeficiency Virus type 1 envelope exhibiting differential exposure of conserved neutralization epitopes. J Virol 84: 2573-2584.
67. Gomez-Roman VR, Florese RH, Patterson LJ, Peng B, Venzon D, et al. (2006) A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity. J Immunol Methods 308: 53-67.
68. Goldman AS, (2007) The immune system in human milk and the developing infant. Breastfeed Med 2: 195-204.
69. Yilmaz HL, Saygili-Yilmaz ES, Gunesacar R, (2007) Interleukin-10 and-12 in human milk at 3 stages of lactation: a longitudinal study. Adv Ther 24: 603-610.
70. Piantadosi A, Panteleeff D, Blish CA, Baeten JM, Jaoko W, et al. (2009) Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression. J Virol 83: 10269-10274.
71. Asensi MT, Martinez-Costa C, Buesa J, (2006) Anti-rotavirus antibodies in human milk: quantification and neutralizing activity. J Pediatr Gastroenterol Nutr 42: 560-567.
72. Battle-Miller K, Eby CA, Landay AL, Cohen MH, Sha BE, et al. (2002) Antibody-dependent cell-mediated cytotoxicity in cervical lavage fluids of human immunodeficiency virus type 1-infected women. J Infect Dis 185: 439-447.
73. Lü FX, (2000) Predominate HIV1-specific IgG activity in various mucosal compartments of HIV1-infected individuals. Clin Immunol 97: 59-68.
74. Raux M, Finkielsztejn L, Salmon-Céron D, Bouchez H, Excler JL, et al. (1999) Comparison of the distribution of IgG and IgA antibodies in serum and various mucosal fluids of HIV type 1-infected subjects. AIDS Res Hum Retroviruses 15: 1365-1376.
75. Bélec L, Dupré T, Prazuck T, Tévi-Bénissan C, Kanga JM, et al. (1995) Cervicovaginal overproduction of specific IgG to human immunodeficiency virus (HIV) contrasts with normal or impaired IgA local response in HIV infection. J Infect Dis 172: 691-697.
76. Fiore JR, Laddago V, Lepera A, La Grasta L, Di Stefano M, et al. (2000) Limited secretory-IgA response in cervicovaginal secretions from HIV-1 infected, but not high risk seronegative women: lack of correlation to genital viral shedding. New Microbiol 23: 85-92.
77. Baum LL, Cassutt KJ, Knigge K, Khattri R, Margolick J, et al. (1996) HIV-1 gp120-specific antibody-dependent cell-mediated cytotoxicity correlates with rate of disease progression. J Immunol 157: 2168-2173.
78. Banks ND, Kinsey N, Clements J, Hildreth JE, (2002) Sustained antibody-dependent cell-mediated cytotoxicity (ADCC) in SIV-infected macaques correlates with delayed progression to AIDS. AIDS Res Hum Retroviruses 18: 1197-1205.
79. Gomez-Roman VR, Patterson LJ, Venzon D, Liewehr D, Aldrich K, et al. (2005) Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251. J Immunol 174: 2185-2189.
80. Bottiger B, Ljunggren K, Karlsson A, Krohn K, Fenyo EM, et al. (1988) Neutralizing antibodies in relation to antibody-dependent cellular cytotoxicity-inducing antibodies against human immunodeficiency virus type I. Clin Exp Immunol 73: 339-342.
81. Yang X, Kurteva S, Ren X, Lee S, Sodroski J, (2005) Stoichiometry of envelope glycoprotein trimers in the entry of human immunodeficiency virus type 1. J Virol 79: 12132-12147.
82. Ahmad R, Sindhu ST, Toma E, Morisset R, Vincelette J, et al. (2001) Evidence for a correlation between antibody-dependent cellular cytotoxicity-mediating anti-HIV-1 antibodies and prognostic predictors of HIV infection. J Clin Immunol 21: 227-233.
83. Forthal DN, Landucci G, Daar ES, (2001) Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells. J Virol 75: 6953-6961.
84. Forthal DN, Landucci G, Haubrich R, Keenan B, Kuppermann BD, et al. (1999) Antibody-dependent cellular cytotoxicity independently predicts survival in severely immunocompromised human immunodeficiency virus-infected patients. J Infect Dis 180: 1338-1341.
85. Forthal DN, Landucci G, Keenan B, (2001) Relationship between antibody-dependent cellular cytotoxicity, plasma HIV type 1 RNA, and CD4+ lymphocyte count. AIDS Res Hum Retroviruses 17: 553-561.
86. Sun Y, Asmal M, Lane S, Permar SR, Schmidt SD, et al. (2011) Antibody-Dependent Cell-Mediated Cytotoxicity in Simian Immunodeficiency Virus-Infected Rhesus Monkeys. J Virol 85: 6906-12.
87. Xiao P, Zhao J, Patterson LJ, Brocca-Cofano E, Venzon D, et al. (2010) Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques. J Virol 84: 7161-7173.
88. Barouch DH, Liu J, Li H, Maxfield LF, Abbink P, et al. (2012) Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature.
89. Forthal DN, Gilbert PB, Landucci G, Phan T, (2007) Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate. J Immunol 178: 6596-6603.
90. Hessell AJ, Rakasz EG, Poignard P, Hangartner L, Landucci G, et al. (2009) Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog 5: e1000433.